129 related articles for article (PubMed ID: 2113064)
1. Effects of subchronic treatment with natural human interferons on antipyrine clearance and liver function in patients with chronic hepatitis.
Echizen H; Ohta Y; Shirataki H; Tsukamoto K; Umeda N; Oda T; Ishizaki T
J Clin Pharmacol; 1990 Jun; 30(6):562-7. PubMed ID: 2113064
[TBL] [Abstract][Full Text] [Related]
2. Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.
Bauer LA; O'Sullivan T; Reiss WG; Horn JR; Opheim K; Strandness DE; Carithers RL
Br J Clin Pharmacol; 1994 Apr; 37(4):375-81. PubMed ID: 8018459
[TBL] [Abstract][Full Text] [Related]
3. Prediction of response to interferon in patients with chronic active hepatitis C, and evidence that this improves hepatic metabolic function.
Farrell GC; Lin R; Coverdale S
Gastroenterol Jpn; 1991 Jul; 26 Suppl 3():243-6. PubMed ID: 1909273
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of antipyrine metabolism by interferon.
Williams SJ; Farrell GC
Br J Clin Pharmacol; 1986 Nov; 22(5):610-2. PubMed ID: 3790409
[TBL] [Abstract][Full Text] [Related]
5. Serial antipyrine clearance studies detect altered hepatic metabolic function during spontaneous and interferon-induced changes in chronic hepatitis B disease activity.
Williams SJ; Farrell GC
Hepatology; 1989 Aug; 10(2):192-7. PubMed ID: 2744731
[TBL] [Abstract][Full Text] [Related]
6. Antipyrine clearance and response to interferon treatment in patients with chronic active hepatitis C.
Coverdale S; Byth K; Field J; Liddle C; Lin R; Farrell GC
Hepatology; 1995 Oct; 22(4 Pt 1):1065-71. PubMed ID: 7557852
[TBL] [Abstract][Full Text] [Related]
7. Elimination of antipyrine and its metabolites in interferon treated hepatitis C.
Sieck JO; el-Yazigi A; Ali H; Døssing M; Saour J; Raines DA; Ernst P
Hum Exp Toxicol; 1994 Sep; 13(9):598-601. PubMed ID: 7986571
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha increases prostaglandin E2 production by cultured liver biopsy in patients with chronic viral hepatitis: can non-steroidal anti-inflammatory drugs improve the therapeutic response to interferon?
Andreone P; Cursaro C; Gasbarrini G
J Hepatol; 1993 Sep; 19(2):228-31. PubMed ID: 8301055
[TBL] [Abstract][Full Text] [Related]
9. Interferon alpha and gamma positive mononuclear cells and HLA antigen expression on hepatocyte membrane in the liver in chronic type B and non-A, non-B hepatitis.
Arao M; Kakumu S; Tahara H; Yoshioka K; Sakamoto N
Gastroenterol Jpn; 1989 Jun; 24(3):255-61. PubMed ID: 2501137
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic non-A non-B hepatitis with human interferon beta: a preliminary study.
Kiyosawa K; Sodeyama T; Nakano Y; Yoda H; Tanaka E; Hayata T; Tsuchiya K; Yousuf M; Furuta S
Antiviral Res; 1989 Oct; 12(3):151-61. PubMed ID: 2516430
[TBL] [Abstract][Full Text] [Related]
11. Antipyrine clearance and metabolite excretion in patients with chronic hepatitis C.
Ali HA; el-Yazigi A; Sieck JO; Ali MA; Raines DA; Saour J; Ernst P; Khan B; Døssing M
J Hepatol; 1995 Jan; 22(1):17-21. PubMed ID: 7751582
[TBL] [Abstract][Full Text] [Related]
12. [Interferon therapy in chronic active viral hepatitis].
Lengyel G; Fehér J
Orv Hetil; 1995 Jan; 136(1):3-7. PubMed ID: 7531317
[TBL] [Abstract][Full Text] [Related]
13. [Ursodeoxycholic hemisuccinate in the treatment of chronic active hepatitis. A controlled clinico-therapeutic study].
Buzzelli G; Moscarella S; Focardi G; Dattolo P; Giusti A; Calviani L; Relli P; Gentilini P
Minerva Med; 1992 Sep; 83(9):537-40. PubMed ID: 1436604
[TBL] [Abstract][Full Text] [Related]
14. [Endogenous bile acids in the blood as a functional test in chronic liver diseases. I. Comparison with the antipyrine elimination test].
Habior A
Pol Arch Med Wewn; 1982; 68(3):125-32. PubMed ID: 7170227
[No Abstract] [Full Text] [Related]
15. Hepatitis B vaccine and antipyrine clearance.
Bachmann K; Schwartz J; Jauregui L; Forney R
J Med; 1985; 16(4):453-9. PubMed ID: 2937866
[TBL] [Abstract][Full Text] [Related]
16. [The rate of antipyrine metabolism in cancer patients administered specific therapy].
Bogush TA; Tseĭtlin GIa; Bukhny AF
Vopr Onkol; 1992; 38(11):1288-93. PubMed ID: 1343156
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of theophylline metabolism by interferon.
Williams SJ; Baird-Lambert JA; Farrell GC
Lancet; 1987 Oct; 2(8565):939-41. PubMed ID: 2444839
[TBL] [Abstract][Full Text] [Related]
18. [Quantification of the drug-metabolizing enzyme system in liver diseases: a comparison between antipyrine saliva clearance and the aminopyrine breath test].
von Mandach U; Jost G; Preisig R
Schweiz Med Wochenschr; 1985 May; 115(19):651-8. PubMed ID: 3923620
[TBL] [Abstract][Full Text] [Related]
19. Antipyrine kinetics in liver disease and liver transplantation.
Mehta MU; Venkataramanan R; Burckart GJ; Ptachcinski RJ; Yang SL; Gray JA; Van Thiel DH; Starzl TE
Clin Pharmacol Ther; 1986 Apr; 39(4):372-7. PubMed ID: 3514052
[TBL] [Abstract][Full Text] [Related]
20. Impairment of hepatic drug metabolism in patients with acute viral hepatitis.
Narang AP; Datta DV; Nath N; Mathur VS
Eur J Drug Metab Pharmacokinet; 1982; 7(4):255-8. PubMed ID: 7166177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
